Log in

OTCMKTS:IPSEYIPSEN S A/S Stock Price, Forecast & News

$24.03
0.00 (0.00 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$24.03
Now: $24.03
$24.03
50-Day Range
$20.50
MA: $22.19
$25.10
52-Week Range
$9.10
Now: $24.03
$28.62
VolumeN/A
Average Volume817 shs
Market CapitalizationN/A
P/E Ratio12.71
Dividend YieldN/A
Beta1.31
Ipsen S.A. operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity. The company also provides NutropinAq, a liquid formulation, for treating growth failure in children due to growth hormone deficiency in adults; and Increlex used for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta, a formulation for use in the treatment of chronic and acute diarrhea; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; Fortrans for the treatment of intestinal cleaning; Eziclen, an osmotic laxative indicated for the cleaning of bowel; Etiasa for the treatment of inflammatory bowel diseases; and Tanaka for mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for the treatment of gout; Prontalgine, an analgesic for the treatment of moderate to severe pain; Buscopan, an antispasmodic; Suppositoria Glycerini, a laxative; and Mucothiol and Mucodyne, which are expectorants for cough and flu. Ipsen S.A. has a strategic agreement with Arix Bioscience plc to develop and commercialize various therapies. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.
Read More
IPSEN S A/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.84 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:IPSEY
CUSIPN/A
CIKN/A
Phone33-01-58-33-50-00

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.02 billion
Cash Flow$2.40 per share
Book Value$5.86 per share

Profitability

Miscellaneous

Employees5,800
Next Earnings DateN/A
OptionableNot Optionable
$24.03
0.00 (0.00 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IPSEY News and Ratings via Email

Sign-up to receive the latest news and ratings for IPSEY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











IPSEN S A/S (OTCMKTS:IPSEY) Frequently Asked Questions

How has IPSEN S A/S's stock been impacted by COVID-19 (Coronavirus)?

IPSEN S A/S's stock was trading at $14.4150 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IPSEY stock has increased by 66.7% and is now trading at $24.0250.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of IPSEN S A/S?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IPSEN S A/S in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for IPSEN S A/S
.

Has IPSEN S A/S been receiving favorable news coverage?

Media headlines about IPSEY stock have been trending negative this week, InfoTrie reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. IPSEN S A/S earned a news sentiment score of -2.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about IPSEN S A/S
.

Who are some of IPSEN S A/S's key competitors?

Who are IPSEN S A/S's key executives?

IPSEN S A/S's management team includes the following people:
  • Mr. David D. Meek, CEO & Director (Age 56)
  • Mr. Aymeric Le Chatelier, Exec. VP & CFO (Age 50)
  • Dr. Aidan Murphy, Exec. VP of Technical Operations (Age 53)
  • Dr. Alexandre P. Lebeaut, Exec. VP of R&D and Chief Scientific Officer (Age 62)
  • Ms. Eugenia Litz, VP of Investor Relations

What is IPSEN S A/S's stock symbol?

IPSEN S A/S trades on the OTCMKTS under the ticker symbol "IPSEY."

How do I buy shares of IPSEN S A/S?

Shares of IPSEY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IPSEN S A/S's stock price today?

One share of IPSEY stock can currently be purchased for approximately $24.03.

What is IPSEN S A/S's official website?

The official website for IPSEN S A/S is www.ipsen.com.

How can I contact IPSEN S A/S?

IPSEN S A/S's mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The company can be reached via phone at 33-01-58-33-50-00 or via email at [email protected]

This page was last updated on 8/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.